52 results
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ZMA001 in Healthy Subjects
Healthy volunteers 18-60 years old are needed to test an investigational drug that was developed to reduce blood pressure in the lungs. The PAH team from @NHLBI hope that this investigational study drug may be helpful in treating patients with PAH in the future.
Learn More
Observational Study of Cardiac Arrhythmias in Subjects Treated with BTK Inhibitors
Pharmacologic therapy with Bruton's tyrosine kinase (BTK) inhibitors is associated with an increased risk of heart problems like atrial fibrillation, bleeding, and high blood pressure (hypertension) which can lead to sudden death. There is currently no standard for cardiac screening or monitoring patients on BTK inhibitors. Researchers at the National Heart, Lung, and Blood Institute (NHLBI) are investigating the relationship between the development of heart problems in patients on BTKi as it relates to other variables.
Learn More
Research Study for Severe Aplastic Anemia (SAA)
Doctors at the National Institutes of Health (NIH) are conducting a research study to determine the viability and safety of early initiation of oral therapy with cyclosporine and eltrombopag in patients with severe aplastic anemia (SAA).
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting with Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) creates an imbalance in the innate immune system responsible for chronic inflammation. A study at NHLBI is looking into a Vitamin B supplement, nicotinamide riboside (NR), to see if it improves immune system function in people with SLE. People with SLE will be asked to take the supplement or placebo for 12 weeks. Healthy control subjects will be enrolled to compare baseline blood results but will not take the supplement.
Learn More